Shaoqiong Liu

Shaoqiong Liu

Auto-generated profile, based on publicly available information

Shaoqiong Liu

ACM Biolabs Pte Ltd, Singapore, 638075, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
SLShaoqiong Liu
Shaoqiong Liu
FWFeng Wen
Feng Wen
PMPadmalosini Muthukumaran
Padmalosini Muthukumaran
MRMoumita Rakshit
Moumita Rakshit
CLChau Sang Lau
Chau Sang Lau
STSwee Hin Teoh
Swee Hin Teoh

8 April 2026 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
SLShaoqiong Liu
Shaoqiong Liu
SLSer Yue Loo
Ser Yue Loo
JLJian Hang Lam
Jian Hang Lam
WPWei Xiang Poh
Wei Xiang Poh
YLYan Jun Lee
Yan Jun Lee
MNMadhavan Nallani
Madhavan Nallani
Toll-like receptor 7/8 (TLR7/8) agonists have shown promise as immune stimulants in cancer immunotherapy but have had limited clinical success, largely hampered by safety concerns associated with systemic administration. To overcome this, the design of new molecules featuring lipophilic substituents and encapsulation into nanocarriers for localized delivery offer a rational strategy to enhance therapeutic efficacy while potentially reducing off-target effects. Herein, we report the polymersome-based delivery of a next-generation TLR7/8 agonist (S)-1-(1-(4-butoxyphenyl)-3-ethoxypropan-2-yl)-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (3M-060), a novel compound with superior immunostimulatory potency encapsulated in nanoscale size polymersomes (ACM-3M-060). ACM-3M-060 elicited stronger induction of pro-inflammatory cytokines than resiquimod (R848) loaded polymersomes (ACM-R848) in human peripheral blood mononuclear cells (PBMCs), while preserving the native activity of the free drug. In a murine CT26 tumor model, intratumoral administration of an ACM-3M-060 analogue labeled with rhodamine led to prolonged retention in the tumor, enhanced drug uptake in the tumor-draining lymph nodes (DLNs) and reduced systemic exposure. Notably, ACM-3M-060 achieved superior tumor growth inhibition compared to the free drug, with a proportion of mice achieving complete tumor regression. Rechallenge with CT26 cells in these animals failed to establish tumors, demonstrating durable antitumor immune memory. This therapeutic effect is primarily driven by TLR7/8-mediated immunomodulation and increased expression of markers of T-cell activity. These findings demonstrate that polymersome delivery enables the safe and effective local administration of potent TLR7/8 agonists such as 3M-060 for cancer immunotherapy.